Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections.
Nitazoxanide , a nitrothiazole derivative, was tested in 22 patients infected with Taenia saginata and 18 infected with Hymenolepis nana. A single 25 mg/kg body weight dose was effective against T. saginata, while twice this dose level (50 mg/kg), also as a single dose, was required for treating H. nana infection. Tolerance of the drug was good at both dose levels used.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000923:Anticestodal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006925:Hymenolepiasis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009574:Nitro Compounds; D013622:Taeniasis / Q000188:drug therapy*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*
D000923:Anticestodal Agents; D009574:Nitro Compounds; D013844:Thiazoles; C041747:nitazoxanide